Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL).
Reinheit:
95%
CAS Nummer:
[1073059-33-2]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
